Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Top Fascinating Organic products: Which One Might You Want to Attempt? - 2'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity
- 3Merz says army could be involved in mine-clearing from Hormuz
- 4How food assistance programs can feed families and nourish their dignity
- 5IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- 4 African Vacationer Locations
- IDF strikes Hamas terror base in Lebanon, Health Ministry says 11 killed
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Born under fire: MDA delivers baby in Jerusalem minutes before rushing to shelter
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo.
